Opens in a new tab or window A literature review has confirmed that the Eczema Area and Severity Index (EASI) is an effective tool for measuring the severity and extent of atopic dermatitis (AD ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

As many as 40% of patients had complete skin clearance at 12 weeks by the Eczema Area and Severity Index (EASI 100). "QY201 ...

Treatment with both these dose levels met the study’s co-primary endpoints of EASI-75 (at least 75% reduction in disease severity) and validated Investigator's Global Assessment for Atopic ...

There are a number of metrics. There are scales, like the EASI scale, Eczema Area and Severity Index, used all the time. It's the lingua franca of clinical trials. So it's what we have to use as ...

The effectiveness of upadacitinib was analysed using the Eczema Area and Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), Sleep Loss–Numerical Rating Scale (S-NRS), and ...

At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction from baseline in Eczema Area and Severity Index score (EASI-75), a 29.5% difference vs. placebo (p < 0.001).

In the high-dose group, 42.3% of patients achieved EASI-75 (at least 75% reduction ... payment of $400 million to Kyowa. Apart from eczema, the companies are also developing the drug for prurigo ...